About Etheros Pharmaceuticals
Etheros Pharmaceuticals is a private company based in Nashville, Tennessee, incorporated in 2022 in Delaware. It has reported $1,675,000 raised in three offerings on Form D since December 2023. Its chief executive is John Scannell.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | Jun 10, 2025 | $600,000fully sold | 6 | $100K | Simple agreement for future equity (SAFE)Rule 506(b) | Form D ↗ |
| Nov 6, 2023 | Dec 20, 2023 | $300,000fully sold | 2 | $150K | Simple agreement for future equity (SAFE)Rule 506(b) | Form D ↗ |
| Feb 20, 2023 | Dec 20, 2023 | $775,000fully sold | 5 | $155K | Simple agreement for future equity (SAFE)Rule 506(b) | Form D ↗ |
| Total, three offerings | $1,675,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Etheros Pharmaceuticals's Form D filed Jun 10, 2025.
SC
Subhasish Chakraborty
Executive officer
JS
John Scannell
CEO and director
MF
Marc Feldmann
Director
FI
Francis Knuettel II
Director
LD
Laura Dugan
Director